UCL’s Advanced Centre for Biochemical Engineering is harnessing the flexible automation capabilities of its Freedom EVO® workstations to explore novel bioprocessing applications, with a focus on the production of ‘next generation’ medicines including protein-derived therapeutics, vaccines and cells for therapy.
The Department of Psychology at TU Dresden is taking advantage of the quality and reproducibility of various IBL International immunoassays – including the Cortisol Saliva Luminescence Immunoassay – to investigate the link between steroid hormones and stress.
Extended periods of walkaway operation are essential to the work carried out by Spanish energy producer Repsol, which relies on two Freedom EVO® platforms and Tecan’s 350 μl nested liquid handling disposable tips for its research into alternative energy sources.
Novartis’ Drug Metabolism and Pharmacokinetics (DMPK) Biologics Division, based in Basel, Switzerland, has developed a flexible, fully automated workflow for blood serum sample preparation and ELISA processing by combining two Freedom EVO® 150 workstations.
With an ever-increasing workload, Germany’s Munich Leukemia Laboratory has automated its cytogenetics protocols on five Freedom EVO® workstations, enabling leaner, standardized, more efficient processing and minimizing the potential for human error.
The launch of the latest Fluent laboratory automation solution has brought the advantages of this application-oriented platform to a host of new users, offering walkaway compound management and assay plate generation to complement the existing end-to-end automation of cell-based and biochemical assay protocols.
Since its launch at SLAS 2015 in February, the park 10M has gained interest from across the life sciences community, with researchers around the world beginning to explore the advanced capabilities of this exciting new system for applications including DNA quantification, microbiology research and cell-based assays.